Pregnancy outcome in patients with a medical history of immunoglobulin A vasculitis: a case-control study.


Journal

Scandinavian journal of rheumatology
ISSN: 1502-7732
Titre abrégé: Scand J Rheumatol
Pays: England
ID NLM: 0321213

Informations de publication

Date de publication:
13 Jul 2023
Historique:
medline: 13 7 2023
pubmed: 13 7 2023
entrez: 13 7 2023
Statut: aheadofprint

Résumé

Data on obstetric outcomes in patients with a history of immunoglobulin A vasculitis (IgA-V) are lacking. The aim of this study was to assess maternal, neonatal, and vasculitis outcomes during pregnancy. We conducted a French retrospective case-control study. Pregnancies of patients with a history of IgA-V (cases) were retrospectively studied and compared to pregnancies in women who developed IgA-V after their pregnancies and to pregnancies in healthy women (controls). Twenty-six pregnancies in patients with a history of IgA-V were included and compared to 15 pregnancies in women who later developed IgA-V and 52 pregnancies in healthy women. Both gestational hypertension and pre-eclampsia were more frequent in the case group than in the other groups (23% vs 0% vs 0%, p < 0.01; 12% vs 7% vs 0%, p = 0.04). Hypertensive disorder of pregnancy occurred more frequently in patients with pre-existing kidney disease (78% vs 12%, p < 0.01). Caesarean section was more often performed in the case group than in the other groups (27% vs 0% vs 10%, p = 0.04). No foetal loss or maternal deaths occurred. There were no differences in delivery term or birth weight. No vasculitis flares were observed during pregnancy. Women with a history of IgA-V appear to be at higher risk for gestational hypertension and pre-eclampsia, especially in cases with renal involvement; however, both mother and newborn outcomes appear to be favourable.

Identifiants

pubmed: 37439394
doi: 10.1080/03009742.2023.2226518
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-8

Auteurs

M-C Besse (MC)

Department of Internal Medicine and Clinical Immunology, CHU de Tours, Tours, France.
Tours University, Tours, France.

F Perrotin (F)

Tours University, Tours, France.
Department of Obstetrics and Gynecology, CHU de Tours, Tours, France.

A Aouba (A)

Department of Internal Medicine and Clinical Immunology, CHU de Caen, Caen, France.

S Gallou (S)

Department of Internal Medicine and Clinical Immunology, CHU de Caen, Caen, France.

A Karras (A)

Department of Nephrology, Hôpital Européen Georges Pompidou, Assistance publique des Hôpitaux de Paris, Paris, France.

E Pillebout (E)

Department of Nephrology, Hôpital Saint Louis, Assistance publique des Hôpitaux de Paris, Paris, France.

G Urbanski (G)

Department of Internal Medicine, CHU d'Angers, Angers, France.

J-S Allain (JS)

Department of Internal Medicine, CH de Saint Malo, Saint Malo, France.

C Merlot (C)

Department of Internal Medicine, CHR Orléans, Orléans, France.

S Humbert (S)

Department of Internal Medicine, CHRU de Besancon, Besancon, France.

Y Ramdani (Y)

Department of Internal Medicine and Clinical Immunology, CHU de Tours, Tours, France.
Tours University, Tours, France.

N Ferreira-Maldent (N)

Department of Internal Medicine and Clinical Immunology, CHU de Tours, Tours, France.

F Maillot (F)

Department of Internal Medicine and Clinical Immunology, CHU de Tours, Tours, France.
Tours University, Tours, France.

A Audemard-Verger (A)

Department of Internal Medicine and Clinical Immunology, CHU de Tours, Tours, France.
Tours University, Tours, France.

Classifications MeSH